Loading…
A PET study examining pharmacokinetics and dopamine transporter occupancy of two long-acting formulations of methylphenidate in adults
The delivery systems of two long-acting formulations of methylphenidate (MPH) were designed for different durations. Diffucaps bead-delivery system (DBDS)-MPH was designed to last 8 h and osmotically controlled-release oral delivery system (OROS)-MPH was designed to last 12 h. While the plasma pharm...
Saved in:
Published in: | International journal of molecular medicine 2010-02, Vol.25 (2), p.261-265 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | The delivery systems of two long-acting formulations of methylphenidate
(MPH) were designed for different durations. Diffucaps bead-delivery system (DBDS)-MPH
was designed to last 8 h and osmotically controlled-release oral delivery system
(OROS)-MPH was designed to last 12 h. While the plasma pharmacokinetics and timing
of efficacy have been studied, the corresponding central nervous system dopamine
transporter (DAT) occupancies are unknown. In this study, 21 healthy volunteers
underwent PET imaging with 11C Altropane before and after administration of oral
doses of DBDS-MPH and OROS-MPH. Each subject received 40 mg DBDS-MPH and 36 mg
OROS-MPH on different days. PET imaging occurred at 10 h after dosing. Each subject
was injected with 5 mCi of 11C Altropane and serial images of the brain were acquired
over 60 min with a Siemens HR+ PET camera. Binding potentials (BP, k3/k4) were
calculated from time-activity curves using the simplified reference region method
with cerebellum as reference. Transporter occupancy was calculated by standard
methods. At 10 h, plasma d-MPH levels were lower (3.8±1.2 vs. 5.2±2.0) and brain
DAT occupancy was lower (34.8±12.9 vs. 44.3±11.8) for DBDS-MPH than OROS-MPH.
Across the range of values, for each unit of change in plasma d-MPH level there
was a larger change in DAT occupancy with the DBDS-MPH formulation than with the
OROS-MPH formulation. As predicted from previous pharmacokinetic and efficacy
data, the average plasma level and DAT occupancy of 36 mg OROS-MPH was >40
mg DBDS-MPH at 10 h. Moreover, a relatively small difference in plasma levels
(1.4 ng/ml at 10 h) was associated with a more impressive difference in DAT occupancy
(≈10% at 10 h). |
---|---|
ISSN: | 1107-3756 1791-244X |
DOI: | 10.3892/ijmm_00000339 |